Results 191 to 200 of about 2,617,552 (333)

Combined effect of increasing the post‐reformer temperature and adding red mud as a secondary catalyst in the thermocatalytic reforming of digestate

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract This work studies the combined effect of increasing the post‐reformer temperature and introducing red mud as a support catalyst in the thermocatalytic reforming (TCR®) of digestate. The TCR® method, developed by the Fraunhofer Institute for Environmental, Safety and Energy Technology UMSICHT (abbreviated as Fraunhofer UMSICHT), is an extension
Hillary Onyishi   +4 more
wiley   +1 more source

Valorization of paper sludge for bioethanol and biogas production

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study evaluated the physicochemical properties and bioenergy potential of three distinct paper sludges: virgin pulp sludge (VP‐PS), corrugated cardboard sludge (CR‐PS), and tissue and printing paper sludge (TPR‐PS). From the experimental runs, VP‐PS exhibited the highest ethanol yield (46.8 ± 3.7 g L−1, 87.4% conversion), which can be ...
Anné Williams   +5 more
wiley   +1 more source

A systematic scoping review of metrics utilized to measure antibiotic consumption in hospital settings

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Antimicrobial stewardship (AMS) programs were introduced to promote the judicious use of antimicrobials and to combat antimicrobial resistance. Quantifying antibiotic consumption is an important part of AMS initiatives to achieve these objectives.
Marjan Kandimahforoujaki   +3 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Home - About - Disclaimer - Privacy